Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice - Besançon, A; Goncalves, T; Valette, F (Diabetologia, 2018)